Cumberland Pharmaceuticals Inc.

Company focus

Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription drugs. Its primary U.S. markets are hospital acute care, gastroenterology, and oncology. The company employs hospital, field, and oncology sales forces in the U.S. and works with international partners to register and distribute medicines.

Product portfolio

• Acetadote (acetylcysteine) injection — marketed in the U.S.; EDTA-free formulation with expanded labeling; protected by U.S. patents and exclusivity arrangements.
• Caldolor (ibuprofen) injection — marketed; next-generation premixed presentation approved; label expansions include pediatric use (infants 3 months and older) and pre-surgical use.
• Kristalose (lactulose) oral solution — marketed; branded laxative with a dry-powder formulation; co-promotion arrangements with Poly Pharmaceuticals and Foxland Pharmaceuticals.
• Sancuso (granisetron) transdermal patch — marketed in the U.S.; acquired from Kyowa Kirin and supported by Cumberland Oncology.
• Vaprisol (conivaptan) injection — acquired; supply transitioned to a new facility, with FDA issues at the new site and limited supply pending relaunch upon clearance.
• Vibativ (telavancin) injection — acquired; Cumberland handles packaging and launched a 4-vial Starter Pak; manufacturing transferred to a new facility; international licensing in multiple territories.
• Talicia (omeprazole, amoxicillin and rifabutin) oral capsules — U.S. approved and co-commercialized with RedHill Biopharma; Talicia Holdings, Inc. holds worldwide rights; Cumberland conducts U.S. sales promotion and shares net revenues under a co-commercialization model.

Pipeline and development

• Lead candidate: ifetroban, a selective thromboxane A2 (TXA2) receptor antagonist.
• Phase II programs:
  • Duchenne muscular dystrophy–related cardiomyopathy (CPI-IFE-007, FIGHT DMD) — positive topline Phase II results in 2025; Orphan Drug and Rare Pediatric Drug designations; Fast Track designation in February 2026; ongoing FDA pathway discussions and end-of-Phase 2 meetings.
  • Systemic sclerosis (CPI-IFE-004) — enrollment closed in February 2025; topline results for the diffuse cutaneous arm expected by end of Q1 2026.
  • Idiopathic pulmonary fibrosis (CPI-IFE-008, FIGHTING FIBROSIS) — actively enrolling; safety interim analysis completed November 2025; at least 70 subjects enrolled across 17 sites.
• Additional pilot Phase II studies and nonclinical work are underway for other indications. The Cumberland Emerging Technologies (CET) partner program identifies and advances early-stage candidates.

Growth strategy

• Maximize utilization of existing brands and pursue label and indication expansions where feasible.
• Selectively acquire approved brands or late-stage assets with protective intellectual property.
• Develop and incubate pipeline opportunities such as ifetroban and advance CET collaborations for early-stage candidates.
• Use co-promotion partnerships to broaden commercial reach.
• Build international sales through partner agreements while retaining worldwide rights for most brands.
• Maintain financial discipline and positive cash flow while pursuing growth.

International partnerships (selected)

• Phebra Pty Ltd — Acetadote & Caldolor — Australia (marketed).
• D.B. Pharm Korea Co., Ltd. — Caldolor — South Korea (marketed); also registered Vaprisol & Vibativ in Korea.
• R-Pharm JSC — Vibativ — Russia (marketed).
• Tabuk Pharmaceuticals — Vibativ — Saudi Arabia and Jordan (marketed).
• PiSA Pharmaceutical — Caldolor — Mexico (approved).
• SciClone Pharmaceuticals, Inc. — Vibativ — China and Hong Kong (approved).
• WinHealth Pharma Group Co., Ltd. — Acetadote & Caldolor — China and Hong Kong (development; strategic alliance).
• WinHealth (WHC Biopharmaceuticals, Pte. Ltd) — joint venture focused on China/Hong Kong and other Asian markets.
• Additional collaborations to register and commercialize Vibativ, Vaprisol, and other products in select territories.

Customers and revenue concentration

• Three customers accounted for 74% of consolidated gross revenues in 2025:
  • Customer 1: 27%
  • Customer 2: 25%
  • Customer 3: 22%

Employees and facilities

• Employees: 93 (as of December 31, 2025).
• Corporate headquarters: ~16,903 rentable square feet at the Broadwest development, Nashville, TN; lease through November 2035.
• CET Life Sciences Center: ~14,200 square feet of office and wet lab space in Nashville, TN; lease extended through April 2028 (second extension executed in 2023).
• Manufacturing and distribution: third-party manufacturers; Cardinal Health Specialty Solutions handles U.S. distribution logistics in 2025.

Intellectual property and regulatory

• Owns trademarks for all branded products and corporate identity.
• Multiple U.S. and international patents cover Acetadote, Caldolor, Vibativ, Talicia, and related formulations, with expirations spanning the 2020s and into the 2040s (examples: Acetadote patents through 2025–2032; Caldolor patents through 2029–2032; Vibativ patents through 2027 and beyond; Talicia patents through 2042).
• Licensing arrangements exist with licensors for certain products, and the company relies on those arrangements to maintain some patent protections.

Financials and risk disclosures

• The company discloses standard industry risk factors, including economic conditions, regulatory changes, competition, reliance on third-party manufacturers, and potential product liability.
• A revolving credit facility is in place with covenants; the company was in compliance with covenants as of December 31, 2025.
• No cash dividends have been paid historically.

Sustainability and governance

• Incurred sustainability disclosures for 2025: 5 million patient doses distributed; approximately 5,500 pounds of expired/damaged goods disposed; no product recalls.
• Workforce composition: 50% women; 30% minorities.
• Operates the Cumberland Pharma Foundation (501(c)(3)) and maintains a political action committee (PAC).

Summary

Cumberland Pharmaceuticals is a niche branded pharmaceuticals company with a portfolio of marketed products and a clinical-stage pipeline centered on ifetroban. The company pursues selective acquisitions, co-promotion and international partnerships, and CET-driven early-stage opportunities. It operates a focused U.S. commercial organization, relies on third-party manufacturing and distribution, maintains active intellectual property protection, and reported material customer concentration in 2025. The company employs 93 people and maintains headquarters and CET facilities in Nashville, Tennessee.